Evidence map›Paper›PMID 37358463›Full record

Observational studyAntimicrobial agents and chemotherapy2023

QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.

Ali Mohamed Ali, Kendra K Radtke, Anneke C Hesseling, Jana Winckler, H Simon Schaaf, Heather R Draper, Belén P Solans, Louvina van der Laan, Jennifer Hughes, Barend Fourie and 3 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Ali Mohamed AliDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-2853-3928
Kendra K RadtkeDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-0578-6554
Anneke C HesselingDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Jana WincklerDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
H Simon SchaafDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Heather R DraperDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Belén P SolansDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-4621-5480
Louvina van der LaanDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.ORCID 0000-0002-3584-7477
Jennifer HughesDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Barend FourieDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
James NielsenDepartment of Pediatrics, New York University School of Medicine, New York, New York, USA.
Anthony J Garcia-Prats *Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.ORCID 0000-0002-9280-1950
Rada M Savic *Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-3143-5579
Desmond Tutu HIV Foundation · ZAUniversity of California, San Francisco · USIfakara Health Institute · TZNew York University · USUniversity of Wisconsin–Madison · US

Funding

PHARMACOKINETICS AND TOXICITY OF SECONDLINE ANTITUBERCULOSIS DRUGS IN HIV-INFECTER01HD069169 · NICHD · STELLENBOSCH UNIVERSITY · PI HESSELING, ANNEKE CATHARINA · 2011 to 2015
$2.0M
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatmentR01HD083047 · NICHD · STELLENBOSCH UNIVERSITY · PI GARCIA-PRATS, ANTHONY JOSEPH, SAVIC, RADOJKA · 2015 to 2019
$1.6M
NICHD NIH HHS R01 HD069169NICHD NIH HHS R01 HD083047
6 · The paper itself

Abstract

Rifampicin-resistant tuberculosis (RR-TB) involves treatment with many drugs that can prolong the QT interval; this risk may increase when multiple QT-prolonging drugs are used together. We assessed QT interval prolongation in children with RR-TB receiving one or more QT-prolonging drugs. Data were obtained from two prospective observational studies in Cape Town, South Africa. Electrocardiograms were performed before and after drug administration of clofazimine (CFZ), levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), and delamanid. The change in Fridericia-corrected QT (QTcF) was modeled. Drug and other covariate effects were quantified. A total of 88 children with a median (2.5th-to-97.5th range) age of 3.9 (0.5 to 15.7) years were included, of whom 55 (62.5%) were under 5 years of age. A QTcF interval of >450 ms was observed in 7 patient-visits: regimens were CFZ+MFX (

Indexed as

Antitubercular AgentsTuberculosis, Multidrug-ResistantAdolescentChildChild, PreschoolClofazimineElectrocardiographyHumansLevofloxacinRifampinSouth AfricaAntitubercular AgentsClofazimineLevofloxacinRifampindrug-drug interactionpediatricsQT prolongationtuberculosis

Identifiers

PMID37358463
PMCPMC10353402
OpenAlexW4382011279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.